N/A N=22 Clinical Effects of Exercise Program Added to Pulmonary Rehabilitation in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Exercise Tolerance — 817; 792.22 meters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=86 Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults
Dengue
Primary: N Antibody, Geometric Mean Titer(GMT) to Dengue Serotypes 1, 2, 3 and 4 — 2; 2; 2; 13 GMT value
Phase 1 N=18 A Study to Evaluate the Effect of Genotype on LY2216684
Depressive Disorder, Major
Primary: Pharmacokinetics: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity [AUC(0-∞)] of LY2216684 in Cytochrome P450 (CYP)2C19 Extensive Metabolizers (EM)…
Phase 4 N=34 The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma
Hemangioma
Primary: Number of Participants With Clinical Response From Baseline in Hemangioma Volume Measured by MRI or SONO — 14; 16 Participants
N/A N=78 Randomized Control Trial of Second Stage of Labor
Labor Complications
Primary: Number of Patients Delivered by Cesarean — 16; 8 Participants
Phase 3 N=452 ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Primary: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review — 14.7; 9.2 months — p=<0.0001
N/A N=5 Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty
Corneal Ulcer · Leukoma
Primary: Incidence of Treatment-Emergent Adverse Events — 0 events
N/A N=219 Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.
Pain Management · Severe Chronic Pain
Primary: Average Overall Change From Baseline (Visit 1) in Visual Analog Scale of Pain Intensity (VASPI) — -3.23; -15.24; -1.50; -18.40 Units on a scale
N/A N=30 Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer
Prostate Cancer
Primary: Safety - Evaluate the Frequency of Treatment Related Adverse Events — 30 Participants
Phase 2 N=165 A Study of LY2484595 in Japanese Subjects
Dyslipidemias
Primary: Percent Change From Baseline to 12 Weeks in High Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 and Placebo…
Phase 2 N=4 A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: Survival at Day 29 of the Assigned Treatment — 2; 0; 1; 1 Participants
Phase 4 N=43 Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET
Coronary Artery Disease
Primary: Safety and Tolerability of Combined Exercise and Regadenoson Stress — 0; 3; 3; 0 Participants
Phase 1 N=3 C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
Advanced Cancer
Primary: Urinary and Fecal Excretion of LY2603618 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 72.2; 11.0 percentage of total dose
Phase 1 N=26 Study of the Safety of Intravenous Artesunate
Malaria · Malaria, Cerebral
Primary: Number of Participants With AEs — 0; 0; 2; 0 Participants
Phase 2 N=44 A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis
Psoriasis · Plaque Psoriasis
Primary: Change in Overall Disease Severity (ODS) Score — 52.2; 0.0 percentage of participants — p=<0.0001